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gonucleotide decreases the expression of LIM kinase 1 in the 
cancer cell. The method also provides compositions of an 
antisense RNA LIM kinase 1 that can be administered to an 
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way and which further comprises methods for treating and 
monitoring the proliferation and metastasis of cancer cells. A 
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normal cellular function. The concentration of LIMKl has 
previously been found at increased levels in some cancer 
cells; for example, cancer cells that are highly aggressive and 
capable of causing metastasis or the spread of tumors in mice. 
Research has shown that a partial inhibition ofLIMK 1 syn-
thesis using antisense RNA in these cells resulted in the 
inhibition of cell growth and more specifically, regression of 
the invasive property of these cells. 
Efforts to identify compositions which inhibit the expres-
This application is a divisional ofU.S. Ser. No. 12/706,218 
filed Feb. 16, 2010 now issued as U.S. Pat. No. 8,415,315, 
which is a continuation ofU.S. Ser. No. 10/840,737 filed May 
6, 2004 now abandoned, which are incorporated herein in 
their entirety. 
BACKGROUND 
10 sion ofLIMK 1 and, which therefore, should be useful in the 
treatment and prevention of cancer cell metastasis, has led to 
the use of the "antisense" or non-encoding LIM Kinase 1, 
which exhibits an ability to inhibit the expression of LIMK 1 
The following is offered as background information only 15 
and is not admitted to be prior art to the present invention. 
Cancer cells are characterized by an ability to proliferate 
indefinitely and to invade normal tissue cells surrounding a 
cancerous tumor. In addition, many types of cancer cells can 
metastasize throughout the body whereby the tumor may be 20 
disseminated in the cancer patient's body. 
The mechanism of cancer metastasis is presumed as fol-
lows: (1) cancer cells proliferate in a primary cancer colony; 
(2) blood vessels are newly formed; (3) the malignant cancer 
cells infiltrate and penetrate the newly formed blood vessels; 25 
( 4) the cancer cells circulate within the human body; (5) the 
cancer cells reach a target organ; (6) the cancer cells extrava-
sate from blood vessels; (7) the cancer cells proliferate in the 
target organ; and (8) a metastatic focus is formed. 
The cure rate of malignant cancer tumors has increased 30 
with early diagnosis and with the progress of therapies, but 
metastases of malignant tumors are often beyond current 
therapies. Chemotherapies are used to arrest metastases fol-
lowing removal of tumors but often with unsatisfactory 
results. It is therefore desirable to develop more effective 35 
inhibitors against malignant tumor metastases. 
Conventional methods for treating cancer have also 
increased the survival and quality of life for cancer patients. 
Such conventional methods include surgery, for example, 
removal of the prostate gland (radical prostectomy), radio- 40 
therapy, and chemotherapy. In addition, bone marrow trans-
plantation is becoming useful in treating patients with certain 
types of cancers. 
Combination therapies may be used in treating cancer and 
are typically not addictive. In some cases, cross effects and 45 
treatment load can result in a lower effectiveness for the 
combinations, than either treatment alone. 
in certain cancer cells. 
Antisense RNA mediated gene therapy is a widely used 
method of gene inactivation and is suitable for gene therapy 
use. However, RNA mediated gene inactivation does not 
work for all genes, and may not be used as a global method of 
gene inactivation. 
SUMMARY 
Before explaining the disclosed embodiment of the present 
invention in detail it is to be understood that the invention is 
not limited in its application to the details of the particular 
arrangement shown since the invention is capable of other 
embodiments. Also, the terminology used herein is for the 
purpose of description and not of limitation. 
In one embodiment, the present invention provides, for 
example, a method for treating cancers and individuals at risk 
of developing cancers by administering an anti sense RNA of 
LIM Kinase 1. 
In another embodiment, the present invention indicates 
that the expression of LIM kinase, one of the proteins that 
modulates actin dynamics, is over expressed in denocarcino-
matous prostatic epithelium and cancer cell lines. 
In one embodiment of the present invention, there is pro-
vided an advantageous therapy for inhibiting the metastasis of 
cancers cells, including, for example, breast, ovarian, lung, 
and prostate cancer cells. More specifically, the invention, in 
embodiments relates to the use of LIM kinase 1 antisense 
RNA to reduce the synthesis of endogenous LIM kinase 1 in 
prostate cancer cell lines. This reduction has been shown to 
reduce the number of metastizing cancer cells. 
In another embodiment of the invention, a partial reduction 
of LIMKl altered cell proliferation by arresting cells at the 
G2/M phase of the cell cycle. Data has also shown a changed 
cell shape and the associated inhibition of the invasive ten-
dencies of metastatic prostate cancer cells. Ectopic expres-
Other treatments such as radiation, while useful for a wide 
range of cancers, does not typically result in a complete cure. 
Given the severity of many cancers and the mortality rate, a 
drug may be thought of as successful ifit improves the quality 
50 sion ofLIMKl promotes the acquisition of the invasive phe-
notype by benign prostate epithelial cells. Experimental data 
provides evidence of a novel role ofLIMKl in regulating cell 
division and in regulating the invasive properties of prostate 
cancer cells. 
of life by delaying the growth of tumors, or if it prolongs life 
without actually curing the condition. In many circum-
stances, an individual is treated with a specific composition or 
with a combination of therapies that can eliminate from about 55 
90 to about 95% of the malignant cells, but the remaining cells 
can re-grow and metastasize, ultimately resulting in death. 
In yet another embodiment of the invention, results indi-
cate that the invasive properties of prostate cancer cells is not 
mediated by phosphorylation of cofilin. Experimental data 
correlates with the recent observations showing a metastasis-
associated chromosomal gain of 7q11.2 in prostate cancer, 
60 suggesting a possible gain in LIMKl DNA (7q 11.23). 
LIM kinase 1 (LIMK 1) is one of the regulatory proteins 
that modulate the actin cytoskeleton by inactivating an actin-
binding protein, cofilin, through addition of a phosphate 
group to cofilin. Actin cytoskeleton is maintained by the 
constant severing and joining of small units of actin and any 
deviation away from this normal dynamic may lead to abnor-
mal behavior of a particular cell. LIMKl plays an important 
role in maintaining cell architecture through actin cytoskel- 65 
eton. As an important regulator of cell behavior, levels of 
LIMKl need to be regulated in cells for the maintenance of 
Yet another embodiment of the instant invention comprises 
partial amino acid and nucleotide sequences of LIMKl. 
In still another embodiment of the present invention results 
indicate that the anti sense RNA of LIM kinase 1 can be used 
successfully in the functional inactivation of LIM kinase 1. 
In other embodiments of the present invention, antisense 
RNA may be used, for example, to inhibit gene function and 
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to demonstrate that the LIMKl gene may find use, for 
example, as a therapeutic target for developing effective can-
cer drugs. 
In yet another embodiment results indicated, for the first 
time, that LIMK 1 may find use as a novel target for anti sense 5 
RNA mediated gene inactivation. Results also indicate that 
the expression ofLIMK 1 may be used as a predictive marker 
for prostate cancer cell metastasis. 
4 
PC3ASL (FIG. 4d) cells successively induced for 72 hours. 
Cells were arrested at the G /S phase boundary and released. 
FIG. 4b indicates the percentage of cells at different stages of 
the cell cycle. 
FIGS. 4c and 4d show cell cycle profiles of similar pro-
gression of PC3ASL and PC3LacZ cells to the Sand GiM 
phase up to 6 hours after release, but only the PC3LacZ cells 
of FIG. 4c continue to the G1 and S phase, whereas the 
PC3AL cells ofFIG. 4dundergo a GiM arrest from about 10 
BRIEF DESCRIPTION OF THE DRAWINGS 
In a further effort to make the above-recited features and 
aspects of the specific embodiments of the invention, clear, 
more specific descriptions of the invention briefly summa-
rized above may be had by reference to embodiments thereof 
which are illustrated in the drawings. These drawings form a 
part of the specification. It is to be noted, however, that the 
drawings illustrate embodiments of the invention and there-
fore are not to be considered limiting in their scope. 
10 hours onwards. The reduced expression of LIMKl in PC3 
cells is associated with the suppression of cell growth and cell 
cycle arrest in the GiM phase. 
FIG. la shows an immunoblot analysis ofLIMKl in total 
lysates of human prostate cell lines. 
FIGS. lb, le and ld show the expression of LIMKl of 
normal/benign areas in prostrate tissues. 
FIGS. le, lf, and lg show the expression of LIMKl of 
cancerous glands in prostrate tissues. 
FIGS. lb and le show hematoxylin/eosin-stained slides at 
lOOx. magnification. 
FIG. Sa shows transfected cells that were successively 
induced for from about 46 to about 50 hours before being 
15 plated into the invasion chambers. Ectopic expression of 
LIMKl in BPH-1 cells increased invasion significantly after 
induction with ponasterone A, for from about 23 to about 25 
hours, with about a 100% difference in invasion in different 
cell lines. Data represents the mean±S.E. of quantitative 
20 analysis of three independent assays (each from two different 
clones oftransfected PC3 and BPH-1 cells). 
FIGS. Sb and Sc, are bright field images of cells invaded to 
the underside of the control and Matrigel membranes. 
FIG. S d presents staining of LIMKl in BPHL and 
25 BPHLacZ cells showing predominantly cytoplasmic distri-
bution of LIMKl in BPHL cells. Nuclei were stained with 
4,6-diamidino-2-phenylindole at 200x magnification. The 
Reduced expression ofLIMKl is associated with a reversion FIGS. ld and lg show normal and cancerous tissues at 
200x magnification. Arrows in FIGS. le and ld indicate light 
staining in basal cells in normal/benign areas. Arrows in 30 
FI GS. lf and lg indicate intense staining in cells in cancerous 
areas. Cell lines used were PrEC and prostate epithelial cells 
of the invasion ability of PC3 cells. 
FIGS. 6a and 6b shows phase-contrast images of 
PC3LacZ, (FIG. 6a) and PC3ASL cells, (FIG. 6b) after suc-
cessive induction for 72 h. 
in glyceraldehyde-3-phosphate dehydrogenase, GAPDH. FIGS. 6c, 6d, 6e, 6/, 6g and 6h, show dual staining of 
continuously induced PC3LacZ cells (FIGS. 6c, 6e, and 6g) FIGS. 2a and 2b show the LIMKl concentrationinBPH-1 
and PC3 cells before, FIG. 2a and after FIG. 2b immunopre-
cipitation with anti-LIMKl antibody. IB immunoblot. Sup, 
supernatant. 
FIG. 2c represents the in vitro phosphorylation ofrecom-
binant cofilin by LIMKl immunoprecipitated from PC3 cells. 
35 and PC3ASL cells, (FIGS. 6d, 6/, and 6h) with Alexa 488-
conjugated phalloidin and anti-LIMKl, (FIGS. 6c and 6d), 
anti-paxillin, (FIGS. 6e and 6j) or MTl-MMP, (FIGS. 6g and 
6h) antibodies. Arrows indicate localization of LIMKl in 
lamellipodia along with actin in FIG. 6c. Arrows in FIG. 6d 
FIG. 2d shows in vivo phosphorylation of cofilin in BPH-1 
and PC3 cells, and is an Immunoblot analysis of cell lysates 
before immunoprecipitation and shows the initial concentra-
tion of cofilin in both samples in the bottom panel of FIG. 2d. 
40 indicate accumulation of LIMKl between actin stress fibers 
FIG. 2e shows the immunoblot analysis of phosphorylated 
cofilin or cofilin in crude cell extracts using anti-phospho- 45 
cofilin or anti-cofilin antibodies. 
FIGS. 3a and 3b show the RNA blot analysis ofLIMKl in 
PC3ASL (a) and PC3LacZ (b) cells induced successively ( +) 
or not(-). 
FIG. 3c shows the concentration ofLIMKl in transfected 50 
PC3 cells harvested at different time points after successive 
induction. 
FIG. 3d shows the concentration of phosphorylated cofilin 
(P-cofilin) or cofilin in transfected PC3 cells after continuous 
induction. Despite the reduced concentration of LIMKl no 55 
noticeable difference in phospho-cofilin concentration was 
detected in PC3ASL cells Using a Western blot in glyceral-
dehyde-3-phosphate dehydrogenase GAPDH. LIMKl was 
effectively reduced in PC3ASL cells by expression of anti-
sense LIMKl, but there was no concurrent reduction in cofi- 60 
!in phosphorylation. 
and cell boundary. The arrows in FIG. 6e indicate localization 
of paxillin to the small adhesion points at the lamellipodia 
along with actin. The redistribution of paxillin and accumu-
lation in large areas between actin stress fibers and cell 
periphery is show in FIG. 6/, and localization ofMTl-MMP 
(also in the enlarged section) and actin to the lamellipodia is 
shown in FIG. 6g. Scale bar, 10 µm. 
FIGS. 6i and 6j, indicate phase contrast images of 
BPHLacZ, 6i and BPHL, 6j showing the difference in growth 
pattern. Here, reduced expression of LIMKl is associated 
with changes in cell morphology, cytoskeleton organization, 
and the invasive ability of PC3 cells. 
DESCRIPTION 
Definitions 
The term "actin", as used herein refers to a protein of the 
myofibril, localized in the I band; acting along with myosin 
particles, it is responsible for the contraction and relaxation of 
muscle. In the absence of salt, it becomes globular (G-actin), 
and in the presence of potassium chloride and adenosine 
triphosphate it polymerizes, forming long fibers (F-actin). 
FIG. 4a depicts a [3H]thymidine incorporation in PC3ASL 
and PC3LacZ cells induced successively (1) or not (N). Data 
represents values relative to the initial time point (0 hours) 
and as the mean±S.E of three independent experiments. 
FIGS. 4b, 4c, 4d shows the flow cytometric analysis of cell 
cycle transition in synchronized PC3LacZ (FIG. 4c) and 
The term "administer" or "administration" refers to the 
65 delivery of a pharamacological composition of the present 
invention to an individual for the purpose of preventing or 
treating of a cancer. 
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The term "antisense RNA", as used herein refers to a 
single-stranded RNA with a base sequence complementary to 
a segment of another RNA molecule that can specifically bind 
to the target RNA and inhibit its activity. 
The term "antisense DNA", as used herein refers to a 
single-stranded DNA with a base sequence complementary to 
a segment of another DNA molecule that can specifically bind 
to the target DNA and inhibit its activity. 
6 
DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
Before explaining the disclosed embodiments of the 
present invention in detail it is to be understood that the 
invention is not limited in its application to the details of the 
particular arrangements shown since the invention is capable 
of other embodiments. Also, the terminology used herein is 
for the purpose of description and not of limitation. 
To understand the role ofLIMKl in prostate cancer, BPH-
1, PrEC, LNCaP, DU145, P69, M21, M12, PC3AR, PC3Neo, 
and PC3 cells were used as models for benign and cancerous 
prostate cells. The above-mentioned cell lines may be used, 
for example, in studies on the invasive behavior of prostate 
The term "expression" (gene expression), as used herein 
refers to the process by which a gene's coded information is 10 
converted into the structures present and operating in the cell. 
Expressed genes include those that are transcribed into RNA 
but not translated into protein (e.g., transfer and ribosomal 
RNA's). 
15 cancer, which also exhibited increased expression ofLIMKl, 
as compared with BPH-1. Because the function of LIMKl is 
mediated through phosphorylation of cofilin in the reorgani-
zation of actin cytoskeleton, the status of the kinase activity of 
The term "nucleic acid", as used herein is defined as family 
of macromolecules, of molecular masses ranging upward 
from 25,000, found in the chromosomes, nucleoli, mitochon-
dria, and cytoplasm of all cells, and in viruses; in complexes 
with proteins, they are called nucleoproteins. On hydrolysis 20 
they yield purines, pyrimidines, phosphoric acid, and a pen-
tose, either d-ribose or d-deoxyribose; from the last, the 
nucleic acids derive their more specific names, ribonucleic 
acid and deoxyribonucleic acid. Nucleic acids are linear (i.e., 
unbranched) chains of nucleotides in which the 5'-phosphoric 25 
group of each one is esterified with the 3'-hydroxyl of the 
adjoining nucleotide. 
An "isolated nucleic acid" is a nucleic acid the structure of 
immunoprecipitated LIMKl from several of the above-men-
tioned cell lines were studied, which confirmed that the 
endogenous LIMKl was catalytically active. Interestingly, a 
parallel increase in the concentration of endogenous phos-
pho-cofilin was also noted in the cell lines. There was no 
significant decrease in the concentration of phospho-cofilin 
after enforced reduction of the expression ofLIMKl. Results 
indicate that antisense-RNA-mediated LIMKl reduced the 
expression of LIMKl and provides evidence of the involve-
ment of LIMKl in regulation of growth of prostate cancer 
cells, specifically at the G2/M phase of the cell cycle. 
Results indicate a direct role ofLIMKl in G2/M phase of 
the cell cycle, as a partial reduction of LIMKl expression 
induced a GiM phase arrest, for example, in PC3ASL cells. 
Consistent with the effect of LIMKl in the promotion of 
cellular invasiveness, a visible alteration in the cell shape and 
which is not identical to that of any naturally occurring 
nucleic acid or to that of any fragment of a naturally occurring 30 
genomic nucleic acid spanning more than three separate 
genes. The term therefore covers, for example, (a) a DNA 
which has the sequence of part of a naturally occurring 
genomic DNA molecule but is not flanked by both of the 
coding sequences that flank that part of the molecule in the 
genome of the organism in which it naturally occurs; (b) a 
nucleic acid incorporated into a vector or into the nenomic 
DNA of a prokaryote or eukaryote in a manner such that the 
resulting molecule is not identical to any naturally occurring 
vector or genomic DNA; ( c) a separate molecule such as a 
cDNA, genomic fragment, a fragment produced by poly-
merase chain reaction (PCR), or a restriction fragment; and 
35 adhesion pattern was caused by a partial reduction in LIMKl 
in prostate epithelial cells. In a specific embodiment, 
PC3ASL cells showed discrete stress fibers, and a more flat-
tened appearance that was typically observed after Rho acti-
vation. The effect ofLIMKl in facilitating cell invasion is not 
40 mediated through the inactivating phosphorylation of cofilin. 
This observation suggests a novel area of interaction between 
LIMKl and other proteins that are involved in maintenance of 
cell behavior such as invasion and locomotion. The presence 
of two LIM domains and a PDZ domain at the amino-terminal 
( c) a hybrid gene, i.e., a gene encoding a fusion protein. The 
term "oligonucleotide", as used herein is defined as a mol-
ecule comprised of two or more ribonucleotides, and in spe-
cific embodiments, more than three ribonucleotides. Its exact 
size will depend upon many factors which, in tum, depend 
upon the ultimate function and use of the oligonucleotide. 
As used herein, the term "PCR" refers to the polymerase 
chain reaction that is the subject of U.S. Pat. Nos. 4,683,195 
and 4,683,202 to Mullis, as well as other improvements now 
known in the art. 
Two DNA sequences are "substantially homologous" 
when, for example, at least about 7 5%, and more specifically, 
45 end of LIMKl suggests its possible interaction with other 
proteins. It has been theorized that the effect of LIMKl is 
accomplished through protein-protein interaction, a phenom-
enon that is sensitive to the stoichiometric balance and can be 
altered with a partial reduction in LIMKl concentration. The 
50 role ofLIMKl as the regulator ofboth the G 2/M phase check-
point and the invasive property of prostate cancer cells and a 
chromosomal gain on 7q11.2, the region of localization of 
LIMKl gene, for example, in metastatic prostate cancer sug-
gests the possibility ofLIMKl as a cellular oncogene. Iden-
55 tification ofLIMKl as a potential promoter of prostate cancer 
progression may facilitate further characterization of inter-
acting partners involved in progression of primary tumors and 
metastasis of advanced tumors and provide a novel therapeu-
at least from about 90% to about 95% of the nucleotides 
match over the defined length of the DNA sequences. 
Sequences that are substantially homologous can be identi-
fied by comparing the sequences using standard software 
available in sequence data banks, or in a Southern hybridiza-
tion experiment under, for example, stringent conditions as 60 
defined for that particular system. 
tic target for prevention of prostate cancer metastasis. 
LIM kinase 1 (LIMKl) belongs to a novel dual specificity 
(serine/threonine and tyrosine) kinase family that contains 
two amino-terminal LIM domains. The LIMKl gene is 
expressed predominantly in brain tissue and developing neu-
ral tissue. LIMKl gene deletion (microdeletion of chromo-
The term "vector", as used herein refers to a DNA molecule 
that replicates on its own in a host cell and can be used as a 
vehicle in the laboratory for replicating other types of DNA. 
Abbreviations used are: LIMKl, LIM kinase 1; NGF, 
nerve growth factor; EGF, epidermal growth factor; BPH-1, 
benign prostatic hyperplasia cells. 
65 some 7ql 1.23) is typical for individuals with Williams's syn-
drome. Cofilin, a known actin-binding protein is considered 
to be a potent regulator of actin protein dynamics based upon 
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cofilin's activity in F-actin depolymerization. Cofilin is the 
only known substrate of LIMKl. The regulatory function of 
cofilin is inhibited by phosphorylation at the Ser-3 residue by 
LIMKl, which has been known to lead to an accumulation of 
F-actin. The catalytic activity of LIMKl is regulated by dis-
tinct members of the Rho protein subfamily of small GTPases 
(Rho, Rae, and Cdc42), which controls actin filament dynam-
ics and focal adhesion assembly in response to extra- and 
intracellular stimuli. Rho, Rae, and Cdc42 induce formation 
of stress fibers, assembly of lamellipodia and membrane 10 
ruffles, and the regulation of filopodial protrusions, respec-
tively. LIMKl has been shown to mediate specifically Rac-
induced actin cytoskeleton reorganization and focal adhesion 
complexes. Rae-induced activation ofLIMKl is mediated by 
PAK!, which phosphorylates LIMKl on its Thr508 residue. It 15 
has been proposed that Rho and Cdc42-induced cytoskeletal 
changes are mediated through phosphorylation ofLIMKl by 
Rho-dependent protein kinase ROCK and Cdc42-regulated 
protein kinase PAK4 and MRCKa. 
The non-catalytic domain ofLIMKl contains two tandem 20 
repeats of a LIM motif, a putative zinc binding motif, and a 
PDZ domain, which contains two tandem nuclear exit signal 
sequences. LIMKl also contains a nuclear localization sig-
nal-like basic cluster sequence. The non-catalytic domain of 
LIMKl has been shown to effect cytoskeleton reorganization 25 
independent of its kinase activity. Specific regions of the 
non-catalytic domain (LIM or PDZ) inhibit neurite outgrowth 
in differentiating PC12 cells responding to Ras, neuronal 
growth factor (NGF) or a ROCK inhibitor without altering 
endogenous LIMKl activity. This data suggests that the non- 30 
catalytic domain of LIMKl is involved in regulating cellular 
processes though protein-protein interaction. 
LIMKl also physically interacts through its LIM domain 
with the cytoplasmic tail of neuregulins, a family of trans-
membrane proteins that functions as receptor tyrosine kinase 35 
ligands. These proteins are known to be involved in the regu-
lation of synapse formation and maintenance, cell prolifera-
tion, apoptosis, differentiation, and neuronal migration. Dele-
tion experiments have shown that the lack of LIM and PDZ 
domains enhances the effect ofLIMKl on actin cytoskeleton. 40 
In addition, expression of a kinase-inactive form of the pro-
tein blocked the effect of the native LIMKl. These findings 
suggest an inhibitory role of the non-catalytic domain in the 
regulation of the kinase activity associated with LIMKl. 
Reorganization of cytoskeleton is an aspect of motility, 45 
detachment, and invasion of cancer cells. Individual members 
of the Rho protein family, such as Rae and Cdc42, induce 
distinct actin remodeling events, work together at the leading 
edge of the cell, and coordinate lamellipodial and filopodial 
extensions, whereas Rho activates accumulation of stress 50 
fibers through activation of ROCK. The formation and stabi-
lization of actin filaments provides the protrusive force for 
cellular extensions at the leading edge of the migratory cells. 
These events may affect the invasive behavior of the cancer 
cells, as the inhibition of Rho kinase activity has been shown 55 
to reduce the invasive progress of prostate cancer cells in vivo. 
Rho proteins are activated by growth factor receptors and 
their ligands, for example, EGF and NGF and their respective 
receptors erbB2 and Trk. Cellular-erbB2 and Trk are often 
over expressed and activated in various types of cancers 60 
including prostate, lung, breast, and ovarian cancers. Further-
more, c-erbB2 was shown to enhance the invasiveness and 
metastatic potential of cancer cells. Similarly, NGF and Trk 
expressions in prostate cancer cells coincide with transfor-
mation to a malignant phenotype capable of invading the 65 
perineural space and extra capsular metastasis to a distant 
site. As evident from membrane ruffling and lamellipodia 
8 
formation, EGF- and NGF-induced invasion of prostate 
tumor cells is mediated through Rae. It is likely that Rac-
mediated activation of actin reorganization is mediated 
through LIMKl. cDNA microarry and differential display 
reverse-transcription PCR analyses indicate over expression 
ofLIMKl mRNA and LIMKl as the elastin-linked gene in 
prostate adenocarcinoma cells. Experimental data indicates 
that LIMKl is over expressed in prostate adnocarcinomatous 
tissues and in malignant prostate cell lines and may be nec-
essary for the invasive property and growth of prostate cancer 
cells. This effect is not mediated through the inactivation of 
the phosphorylation of cofilin. 
Recent studies show that LIMKl undergoes mitosis-spe-
cific activation by hyperphosphorylation, which is associated 
with a concomitant increase in phosphorylation of cofilin. 
LIMKl becomes activated in prometaphase and metaphase 
and comes back to the basal level as cells enter telophase, 
which suggests that a controlled activity of cofilin by phos-
phorylation and dephosphorylation is necessary for mitosis. 
A direct role of LIMKl in promoting cellular invasion, a 
hallmark of metastasis, is evident based on Matrigel-based 
invasion assay analysis. A partial inhibition of LIMKl 
reduced the percentage of invading cells down to the level 
observed for BPH-1 cells. However, the effect of ectopic 
expression with regards to LIMKl in BPH-1 cells on the 
promotion of the invasion was more pronounced and signifi-
cantly higher than the highly metastatic PC3 cells, suggesting 
a possible role for LIMKl in the acquisition of metastatic 
behavior of prostate tumors. An increased expression of 
LIMKl in metastatic prostate tumors, may indicate an asso-
ciation ofLIMKl expression with advanced prostate cancer. 
It is possible that the effect of growth factors on the increased 
invasion is mediated through LIMKl in advanced prostate 
cancer in which specific receptors for NGF and EGF are over 
expressed. However, it is unclear how the ectopic expression 
of LIMKl promotes cellular invasion in BPH-1 cells, in 
which the upstream effectors ofLIMKl may not be activated 
without specific extra-cellular signals. 
Manimalian LIM kinase 1 is involved in the reorganization 
of the actin cytoskeleton through the inactivating phosphory-
lation of the ADF family protein cofilin that depolymerizes 
actin filaments. Maintenance of actin dynamics in an ordered 
fashion is required for the stabilization of cell shape and for 
the promotion of cell motility of some cell types. Cell shape 
and promotion of cell motility are two phenomena that may 
become altered during acquisition of the metastatic pheno-
type by the cancer cell. Data indicates that when LIMKl is 
over-expressed in manimalian prostate tumors and prostate 
cancer cells, the concentration of phosphorylated cofilin is 
higher in metastatic prostate cancer cells. 
Anti sense agents are tools for use in inhibiting the expres-
sion of target genes in a sequence-specific mamier and have 
found use in functional genomics, target validation, and for 
therapeutic purposes. Different types of anti-mRNA strate-
gies, for example, the use of single stranded antisense-oligo-
nucleotides, the triggering of RNA cleavage through catalyti-
cally active oligonucleotides referred to as ribozymes, and 
RNA interference induced by small interfering RNA mol-
ecules, have been attempted. The successful use of antisense 
agents may depend, for example, on identifying accessible 
sites of the target RNA for oligonucleotide binding, protect-
ing the antisense agents from nucleolytic attack, preventing 
their cellular uptake, and providing for the correct intracellu-
lar localization. Some success has been shown with chemi-
cally modified nucleotides, for example, alkyl modifications 
at the 2' position of the ribose. These chemically modified 
nucleotides have shown improved serum stability, higher tar-
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get affinity and low toxicity. In addition, RNA-cleaving 
ribozymes and deoxy-ribozymes, along with the use of 
21-mer double-stranded RNA molecules for RNA interfer-
ence applications in mammalian cells has shown efficiency in 
the suppression of the expression of specific genes. 
Antisense approaches differ from conventional drugs, 
most of which bind to proteins and thereby modulate their 
function. In contrast, antisense agents act at the mRNA level, 
preventing its translation into protein. Antisense-oligonucle-
otides (AS-ONs) pair with their complementary mRNA, 
whereas ribozymes and DNA enzymes are catalytically 
active oligonucleotides that not only bind, but can also cleave, 
their target RNA. Recently, progress that been made with the 
development and use of chemically modified nucleotides that 
stabilize oligonucleotides against nucleolytic degradation 
and enhance their target affinity. In addition RNA interfer-
ence may be used as an efficient method of suppressing gene 
expression in mammalian cells by the use of 21-23 mer small 
interfering RNA (siRNA) molecules. 
Antisense-oligonucleotides combine many desired proper-
ties, for example, broad applicability, direct utilization of 
sequence information, rapid development at low costs, high 
probability of success and high specificity compared to alter-
native technologies for gene functionalization and targeting. 
Anti sense oligonucleotides have also proved useful in animal 
models for therapeutic purposes. 
Antisense-oligonucleotides may, for example, consist of 
from about 15 to about 20 nucleotides, which are comple-
mentary to their target mRNA. Phosphorothioate (PS) oli-
godeoxynucleotides are one type of oligonucleotide used for 
inhibiting gene expression. In this class of oligonucleotide, 
one of the non-bridging oxygen atoms in the phophodiester 
bond is replaced by sulfur. The introduction of phospho-
rothioate linkages into oligonucleotides was primarily 
intended to enhance their nuclease resistance. 
Phosphorothioate DNAs have a half-life in human serum 
of from about 9 to about 10 hours compared to about 1 hour 
for unmodified oligodeoxynucleotides. In addition to 
nuclease resistance, phosphorothioate DNAs form regular 
Watson-Crick base pairs, activate RNase H, carry negative 
charges for cell delivery and display attractive pharmacoki-
netic properties. 
Another class of antisense oligonucleotides contains alkyl 
modifications at the 2' position of the ribose. 2'-0-methyl and 
2'-0-mehtoxy-ethyl RNA are members of this class. 2'-0-
alky RNA oligonucleotides do not recruit RNase H, their 
antisense effect is due, for example, to a steric block of 
translation. Other antisense oligonucleotides modifications 
may include, for example, C-5 propyne, 2'-0-aminopropyl, 
and dipyridophenazine-DPPZ 
A chemically synthesized anti sense nucleic acid molecule 
or ribozyme may be introduced into a cell by any of a variety 
of methods know in the art (Sambrook et al., supra, 1989, and 
10 
which also can be modified with specific receptors or ligands 
as described above (Morishita et al., J. Clin. Invest., 91:2580-
2585 (1993), incorporated herein by reference; see, also, 
Nabel et al., supra, 1993)). In addition, a nucleic acid mol-
ecule may be introduced into a cell using adenovirus-polyl-
ysine DNA complexes (see, for example, Michael et al., J. 
Biol. Chem., 268:6866-6869 (1993), and incorporated herein 
by reference in its entirety). 
Embodiments of the present invention also includes 
10 nucleic acids that hybridize under stringent hybridization 
conditions, as defined herein, to all or a portion of the nucle-
otide sequence represented by SEQ ID NO: 1 or its comple-
ment. The hybridizing portion of the hybridizing nucleic acid 
varies from about 80%, and for example, at least 95%, or at 
15 least 98% identical to the sequence of a portion or all of a 
nucleic acid encoding a polypeptide, or its complement. 
Hybridizing nucleic acids of the type described herein can be 
used, for example, as a cloning probe, a primer (e.g, a PCR 
primer), or a diagnostic probe. Hybridization of the oligo-
20 nucleotide probe to a nucleic acid sample typically is per-
formed under stringent conditions. Nucleic acid duplex or 
hybrid stability is expressed as the melting temperature or 
Tm, which is the temperature at which a probe dissociates 
from a target DNA. This melting temperature is used to define 
25 the required stringency conditions. If sequences are to be 
identified that are related and substantially identical to the 
probe, rather than identical, then it is useful to first establish 
the lowest temperature at which only homologous hybridiza-
tion occurs with a particular concentration of salt (e.g., SSC 
30 or SSPE). 
Then, assuming that 1 % mismatching results in a 1 ° C. 
decrease in the Tm, the temperature of the final wash in the 
hybridization reaction is reduced accordingly (for example, if 
sequences having >95% identity with the probe are sought, 
35 the final wash temperature is decreased by 5° C.). In practice, 
the change in Tm can be from about 0.5° C. to about 1.5° C. 
per 1 % mismatch. Stringent conditions involve hybridizing at 
about 68° C. in 5x SSC/5xDenhardt's solution/1.0% SDS, 
and washing in 0.2xSSC/0.1 % SDS at about 37° C. Moder-
40 ately stringent conditions include washing in 3xSSC at about 
42° C. The parameters of salt concentration and temperature 
can be varied to achieve the optimal level of identity between 
the probe and the target nucleic acid. Additional guidance 
regarding such condition parameters are readily available in 
45 the art, for example, by Sambrook et al., 1989, Molecular 
Cloning, A Laboratory Manual, Cold Spring Harbor Press, 
N.Y.; and Ausubel et al. (eds.), 1995, Current Protocols in 
Molecular Biology, (John Wiley & Sons, N.Y.) at Unit 2.10, 
both of which are incorporated herein by reference in their 
50 entirety. 
in Ausubel et al., Current Protocols in Molecular Biology, 
Hohn Wiley and Sones, Baltimore, Md. (1994), incorporated 55 
herein by reference in its entirety), including, for example, 
transfection, microinjection, electroporation or the use of 
liposomes. In addition, it is recognized by those skilled in the 
Any individual domain, for example, an LIM, a PDZ, or a 
LIM kinase domain, individually or in combination, may be 
used and/or modified while retaining the activity of the 
polypeptide. 
As used herein, "percent homology" of two amino acid 
sequences or of two nucleic acids may be determined using 
the algorithm of Karlin and Altschul (Proc. Natl. Acad. Sci. 
USA 87:2264-2268, 1990), modified as in Karlin and Alts-
chul (Proc. Natl. Acad. Sci. USA 90:5873-5877, 1993), both art that naked nucleic acid molecules are taken up by cells in 
vivo and, therefore, the antisense nucleic acid molecule of the 
invention may be administered, for example, directly to the 
region containing the cancer cells. More specifically, anti-
sense nucleic acid molecules may be introduced into a cell 
using methods that do not require the initial introduction of an 
encoding nucleic acid molecule into a vector. For example, a 
nucleic acid molecule encoding an antisense LIMK 1 mol-
ecule can be introduced into a cell using a cationic liposome, 
60 of which are incorporated herein by reference in their entirety. 
Such an algorithm is incorporated into the NBLAST and 
XBLAST programs of Altschul et al. (J. Mo!. Biol. 215:403-
410, 1990), incorporated herein by reference in its entirety. 
BLAST nucleotide searches are performed with the 
65 NBLAST program, score=lOO, word length=12, to obtain 
nucleotide sequences homologous to a nucleic acid molecule 
of the invention. BLAST protein searches are performed with 
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the XBLAST program, score=50, word length=3, to obtain 
amino acid sequences homologous to a reference polypeptide 
(e.g., SEQ ID NO: 2). To obtain gapped alignments for com-
parison purposes, Gapped BLAST is utilized as described in 
Altschul et al. (Nucleic Acids Res. 25:3389-3402, 1997), 
incorporated herein in its entirety. When utilizing BLAST 
and Gapped BLAST programs, the default parameters of the 
respective programs (e.g., XBLAST and NBLAST) are used. 
See http://www.ncbi.nlm.nih.gov. 
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dard methods. In addition, the pharmaceutical formulations 
can be administered to the patient via injectable depot routes 
of administration such as by using 1-, 3-, or 6-month depot 
injectable or biodegradable materials and methods. 
Such a composition typically contains from about 0.1 to 
about 90% by weight (such as 1 to 20% or 1 to 10%) of a 
therapeutic agent of the invention in a pharmaceutically 
acceptable carrier. Solid formulations of the composition for 
administration may contain suitable carriers or excipients, 
such as corn starch, gelatin, lactose, acacia, sucrose, microc- 15 
rystalline cellulose, kaolin, mannitol, dicalcium phosphate, 
calcium carbonate, sodium chloride, or alginic acid. Disinte-
grators that can be used include, without limitation, micro-
crystalline cellulose, corn starch, sodium starch lycolate and 
alginic acid. Lubricants that may be used include magnesium 20 
stearates, stearic acid, silicone fluid, talc, waxes, oils, and 
colloidal silica. 
Regardless of the route of administration, the therapeutic 
agent typically is administered at a daily dosage of from about 
0.01 mg/kg to about 30 mg/kg of body weight of the patient, 
for example, from about 1 mg/kg to about 5 mg/kg. The 
pharmaceutical formulation can be administered in multiple 
10 doses per day, if desired, to achieve the total desired daily 
dose. 
The effectiveness of the method of treatment can be 
assessed by monitoring the patient. For example, a decrease 
in the spread or proliferation of prostate cancer cells can be 
detected by monitoring the patient for a dose-dependent 
reduction in prostate-specific antigen (PSA) levels. Dose-
dependent reductions in PSA correlate with a dose-dependent 
decrease in the spread of prostate cancer cells. 
There are several techniques and methods known in the art 
for in vivo identification and monitoring of cancer cell 
metastasis. For example, bone scintigraphy may be used in 
monitoring. Prostate specific membrane antigen (PSMA) 
scintigraphy, is known and is one of the most sensitive imag-
Injectable formulations of the compositions may contain 
various carriers such as vegetable oils, dimethylacetamide, 
dimethylformamide, ethyl lactate, ethyl carbonate, isopropyl 
myristate, ethanol, polyols (glycerol, propylene glycol, liquid 
polyethylene glycol, and the like). For intravenous injections, 
water soluble versions of the compositions may be adminis-
tered by the drip method, whereby a pharmaceutical formu-
lation containing an antifungal agent and a physiologically 
acceptable excipient is infused. Physiologically acceptable 
excipients may include, for example, 5% dextrose, 0.9% 
saline, Ringer's solution or other suitable excipients. Intra-
muscular preparations, e.g., a sterile formulation of a suitable 
soluble salt form of the compositions, can be dissolved and 
administered in a pharmaceutical excipient such as Water-for-
Injection, 0.9% saline, or 5% glucose solution. A suitable 
insoluble form of the compositions may be prepared and 
administered as a suspension in an aqueous base or a phar-
maceutically acceptable oil base, such as an ester of a long 
chain fatty acid (e.g., ethyl oleate). 
A topical semi-solid ointment formulation typically con-
tains a concentration of the active ingredient from about 1 to 
about 20%, e.g., 5 to 10%, in a carrier such as a pharmaceu-
tical cream base. Various formulations of topical use include 
drops, tinctures, lotions, creams, solutions and ointments 
containing the active ingredient and various supports and 
vehicles. The optimal percentage of the therapeutic agent in 
each pharmaceutical formulation varies according to the for-
mulation itself and the therapeutic effect desired in the spe-
cific pathologies and correlated therapeutic regimens. 
25 ing techniques for the initial detection of bone metastases and 
is widely used in the staging of prostatic cancer. PSMA is 
found in normal prostatic epithelial cells and is elevated in 
prostate cancers, especially in poorly differentiated, meta-
static, and hormone refractory carcinomas. Tumor scintigra-
30 phy may be used for, but is not limited to, detection of certain 
primary, metastatic, and recurrent tumors, evaluation of 
abnormal imaging and non-imaging findings in patients with 
a history of certain tumors, and reassessment of patients for 
35 
residual tumor burden after therapy. Bone is the most com-
mon site of circulatory (or haematogenous) metastases from 
prostate cancer. Bony metastases are found in 85% of patients 
dying of the disease. Radionuclide scintigraphy using a radio-
actively labeled chemical is administered to the patient and is 
40 taken up in areas of increased bone turnover or growth. 
Although sensitive, this technique is not specific and false-
positives may be obtained in cases of recent bone trauma, 
degenerative joint disease or Paget's disease. Other imaging 
techniques include single photon emission computed tomog-
45 raphy (SPECT), positron emission tomography (PET), com-
puted tomography (CT), magnetic resonance imaging (MRI), 
and magnetic resonance spectroscopy (MRS). ProstaScint 
Imaging is based on using planar and SPECT imaging to map 
the uptake of capromab pendetide that has been labeled with 
50 a radionucliotide. Capromab pendetide is a monoclonal anti-
body that targets prostate-specific membrane antigen, a trans-
membrane glycoprotein that has been thoroughly character-
ized because of its role as a marker for prostate cancer and 
Conventional methods, known to those of ordinary skill in 
the art of medicine, can be used to administer the pharmaceu-
tical formulations(s) to the patient. For example, any known 
viral vector or any known method for delivering RNA to 
prostate cells may be used. Typically, the pharmaceutical 
formulation will be administered to the patient by applying to 
the skin of the patient a transdermal patch containing the 
pharmaceutical formulation, and leaving the patch in contact 
with the patient's skin generally for from about 1 to about 5 
hours per patch. Other transdermal routes of administration 
(e.g., through use of a topically applied cream, ointment, or 
the like) can be used by applying conventional techniques. 
The pharmaceutical formulation( s) can also be administered 
via other conventional routes (e.g., oral, subcutaneous, intra- 65 
pulmonary, transmucosal, intraperitoneal, intrauterine, sub-
lingual, intrathecal, or intramuscular routes) by using stan-
55 
metastases. As with all scintigraphic studies, correlation of 
findings with results of other imaging and non-imaging 
modalities, as well as with clinical information, is necessary 
for maximum diagnostic yield. 
Prostate Specific Antigen (PSA) measurements are known 
60 in the art and have been shown to be accurate and cost-
effective predictors of prostate cancer cell proliferation. 
In one embodiment the composition may, for example, be 
presented in a pack or dispenser device, such as an FDA 
approved kit, which may contain one or more unit dosage 
forms of the active ingredient. The pack may, for example 
comprise metal or plastic foil. The pack or dispenser device 
may be accompanied by instructions for administration. 
US 8,802,649 B2 
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Example 1 
Cell Culture, Transfection, and Isolation of Stable 
Cell Line 
14 
beads (Sigma) using the procedure as described, and the 
products were resolved in a from about a 10 to about a 14% 
solution ofSDS-PAGE. Labeled cofilin was detected by auto-
radiography and Phosphorlmager analysis. Recombinant 
5 cofilin was expressed in Escherichia coli as a His-tagged 
fusion protein by cloning the open reading frame of human 
cofilin into the T7 polymerase driven pET30Ek/LIC 
(Novagen) expression vector using specific primers (F, 
5'-GACGACGACAAGATGGCCTCCGGTGTGGCTG-3' 
The following cell lines, including, PC3, DU145, LNCaP, 
PrEC, BenignProstatic Hyperplasia (BPH-1), P69, M21, and 
M12 weremaintainedinRPMI (DU145, LNCaP, P69, M21, 
and M12), Ham-12 (PC3), DMEM (BPH-1) and in the spe-
cific medium (PrEC) and grown to log phase before being 
used. PC3 cells were transfected using LipofectAMINE™ 
with the open reading frame of the Lacz gene or the antisense 
cDNA of the coding sequence of LIMKl (1.94 kilo bases), 
both cloned into an ecdysoneinducible mammalian expres-
sion vector pIND. BPH-1 cells (benign pro static hyperplasia) 
were transfected with the open reading frames of LIMKl or 
Lacz cloned in pIND. Cells were cotransfected with the 
vector p VRxR that encodes the subunit of a heterodimer of 
the ecdysone and the retinoid X receptor to establish stable 
cell lines (PC3ASL and PC3LacZ) capable of expressing 20 
antisense LIMKl RNA or Lacz when induced with an ecdys-
one analogue, ponasterone A. Double stable clones were 
selected using from about 450 µg/ml to about 550 µg/ml 
Geneticin™ and from about 45 µg/ml to about 55 µg/ml 
Zeocin™. Stable transfected cells were continuously induced 25 
by adding from about 4 µM to about 6 µM ponasterone A for 
from about 20 to about 24 hours. 
10 (SEQ ID NO. 2), and R, 5'-GAGGAGAAGCCC GGTTCA-
CAAAGGCTTGCCC-3' (SEQ ID NO. 3)). The expression 
construct was used to transform BL21 (DE3) E. coli cells. 
Transformed cells were induced with 1 mM isopropyl-1-thio-
~-D-galactopyranoside at 25° C., and the expressed cofilin 
15 was purified through a Nickel affinity colunm. 
Example 2 
Example 4 
For immune complex kinase assay, LIMKl was immuno-
precipitated from PC3 cells cultured under regular conditions 
using anti-LIMKl antibody and protein G-agarose (Sigma) 
beads. Protein G-agarose beads bound to the immune com-
plex were re-suspended in kinase assay buffer comprising 
from about 45 to about 55 mM HEPES, a pH of from about 7 .0 
to about 8.0, from about 100 to about 200 mM NaCl, from 
about 45 to about 55 M ATP, from about 4 to about 6 mM 
MgCl2 , from about 4 to about 6 mM MnCl2 , from about 9 to 
about 11 mM NaF, from about 0.5 to about 1.5 mM Na3 V04 , 
from about 2 to about 4 nM [y-32P]ATP) and incubated at 
Immunoblotting, Immunohistochemistry, and 
Immunofluorescence 
Total cell lysates were resolved in a from about 10 to about 
30 about 30° C. for from about 15 to about 25 minutes with from 
about 9 to about 11 µg of recombinant cofilin as the substrate. 
The reaction mixture was resolved in a from about 12% to 
about a 16% solution of SDS-PAGE, and phosphorylated 
cofilin was detected by autoradiography and Phosphorlmager 
35 analysis. a 14% solution ofSDS-PAGE and subjected to immunoblot-
ting using anti-LIMKl, anti-cofilin, or anti-phospho-cofilin 
antibodies. Anti-glyceraldehyde-3-phosphate dehydroge-
nase antibody was simultaneously used as an internal control. 
Goat anti-mouse or anti-rabbit antibody was used as the sec-
ondary antibody. Paraffin-embedded tissue sections of nor- 40 
ma! and malignant human prostate were subjected to a pep-
sin-based antigen retrieval protocol followed by incubation 
with anti-LIMKl antibody. A biotinylated multi-link goat 
anti-immunoglobulin for mouse, rabbit, guinea pig, and rat 
was used as the secondary antibody. Positive signals were 
detected by horseradish peroxidase-conjugated streptavidin 
and 3,3'-diaminobenzidine (DAB) as the chromogen. For 
indirect immunofluorescence, PC3ASL and PC3LacZ cells 
were plated on poly-L-lysine-coated glass cover slips and 
continuously induced for from about 70 to about 74 hours. 50 
Cells were permeabilized and dually stained withA!exa Fluor 
488-conjugated phalloidin and anti-LIMKl, anti-paxillin, or 
anti-MTl-MMP antibodies. Cy3-conjugated anti-mouse or 
anti-rabbit antibody (Molecular Probes) was used as the sec-
ondary antibody. Fluorescent images were captured using a 55 
laser-scanning confocal microscope. 
Example 3 
In Vivo Phosphorylation, Expression of 
Recombinant Protein, and Immunecomplex Kinase 
Assay 
BPH-1 and PC3 cells were cultured in the presence of 1.5 
mCi of [32P]orthophosphate forr from about 10 hours. Equal 
amounts of total cell lysates were subjected to immunopre-
cipitation with anti-cofilin antibody and protein A-agarose 
Example 5 
Invasion Assay 
Cells were plated in serum-free media (containing ponas-
terone A for transfected cells) as a control and Matrigel-
coated membrane containing invasion chambers. Cells were 
incubated at about 3 7° C. for from about 20 to about 24 hours 
45 in a co2 incubator using from about a 4 to about a 6% fetal 
bovine serum in the lower chamber as the chemoattractant. 
Invading cells were stained with Diff-Quick™ stain and 
counted. The percentage of metastasizing cells that invaded 
through the Matrigel-coated membranes was calculated by 
comparison with the cells passed through the membranes in 
the control chambers. The results are shown in FIG. 5. 
Example 6 
[
3 H]Thymidine Incorporation, Cell synchronization, 
and Fluorescence-Activated Cell Sorter Analysis 
Asynchronous PC3LacZ and PCASL cells were incubated 
with about 1 µCi of [3H]thymidine in the presence or absence 
60 of ponasterone A. At about 10 minute time intervals after 
induction, cells were treated with a 5% trichloroacetic acid 
solution and lysed using a 0.5 N NaOH solution. Incorpora-
tion of [3H]thymidine to DNA was measured in a scintillation 
counter (Beckman LS 5000 TD). For cell cycle analysis, 
65 PC3LacZ and PC3ASL cells induced at from about every 20 
to about every 24 hours, were synchronized at the G /S phase 
boundary by a double thymidine block by treating them with 
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a solution of from about 1 to about 3 mM thymidine for from 
about 22 to about 26 hours followed by a release of from about 
16 
(FIG. 2, d and e), which demonstrates a parallel increase in 
phosphorylated cofilin within these cells. 
Example 8 
A Partial Inhibition of LIMKl Expression Did not 
Result in Reduced Phosphorylation of Cofilin 
7 to about 9 hours in fresh growth medium and successive 
re-treatment with thymidine (2 mM) for about 16 hours. The 
cells were then released to enter the cell cycle in fresh growth 5 
medium and harvested at specified time intervals. The cells 
were fixed in a solution of from about 0.5 to about 1.5% 
paraformaldehyde in phosphate-buffered saline (PBS), 
washed in PBS, permeabilized with a solution of from about 
0.2% to about 0.3% saponin in PBS, and treated with from 
about 0.5 mg/ml to about 1.5 mg/ml of a solution ofRNase (1 
mg/ml) at from about 37° C. The cells were washed in phos-
phate-buffered saline and stained with a from about 350 to 
about a 450 µg/ml solution of propidium iodide at about 37° 
15 
C. for from about 25 to about 35 minutes. The cells were 
To understand the possible role of over expressed LIMKl 
10 in the acquisition oftumorigenic and metastatic phenotypes, 
antisense-RNA mediated functional inactivation of LIMKl 
analyzed in a flow cytometer, and the raw data was analyzed 
using Modfit (BD Biosciences) software. 
was used; subsequently, a PC3ASL cell line was generated 
which was capable of expressing antisense LIMKl RNA after 
induction with an ecdysone analogue, ponasterone A. A time 
course study using PC3ASL cells and a control transformed 
cell line, PC3LacZ, after continuous induction for from about 
20 to about 22 hours for a total of 72 hours, indicated the 
maximum expression ofLIMKl antisense transcript at about 
72 hours, which was associated with a concurrent decrease in 
Example 7 
LIMKl is Over Expressed in Cancerous Prostate 
Cells and Tissues and is Catalytically Active 
20 the concentration of the sense LIMKl transcript only in the 
induced PC3ASL cells (FIG. 3a). No decrease in the LIMKl 
transcript was apparent in any of the PC3LacZ cells induced 
or not or in un-induced PC3ASL cells (FIG. 3, a and b). A 
parallel reduction in the LIMKl protein concentration con-
25 firmed the decreased synthesis of LIMKl in PC3ASL cells 
(FIG. 3c). Immunoblot analysis using anti-cofilin or anti-
phospho-cofilin antibodies revealed no simultaneous 
decrease in the concentration of phosphorylated cofilin in 
PC3ASL cells (FIG. 3d). This observation suggests, for 
To confirm the differences in the expression of LIMKl in 
prostate cancer, the expression profile ofLIMKl was moni-
tored in various prostate cell lines, for example, PC3, DU145, 
LNCaP, PrEC, Benign Prostatic Hyperplasia (BPH-1), P69, 
M21, and M12 were maintained in RPMI (DU145, LNCaP, 
P69, M21, and M12), Ham-12 (PC3), DMEM (BPH-1) and 
prostate tissues. Results of the monitoring indicated an 
increased expression of LIMKl in aggressive metastatic 
prostate epithelial cells and in some prostatic adenocarcino-
mas (FIG. l). The concentration ofLIMKl in some cancerous 
prostate cell lines (M21 and M12) increased proportionately 
with increasing tumorigenic and aggressive properties when 
compared with normal prostate epithelial cells, P69 and 
BPH-1 cells (FIG. la). An increase of from about 200% to 
about 300% expression ofLIMKl was noted in tumorigenic 
cells, LNCaP, M21 and metastatic cells, PC3, DU145, and 40 
M12 prostate cancer cells when compared with BPH-1 and 
P69 (non-tumorigenic) cells (FIG. la). Compared with pros-
tate epithelial cells, the expression of LIMKl was, for 
example, from about 500% to about 1000% higher in the 
metastatic prostate cancer cells, PC3 and M21 (FIG. la). 45 
Consistent with these findings, immunohistochemical analy-
30 example, that, the residual LIMKl can be catalytically more 
efficient andmaintain an increased concentration of phospho-
rylated cofilin or the enhanced phosphorylation of cofilin was 
not mediated by LIMKl. Although cofilin is the only known 
substrate ofLIMKl, it can be phosphorylated by other serine/ 
35 threonine kinases, such as LIMK2 and TESK1/TESK2. 
Example 9 
Reduced Expression of LIMKl Retarded Cell 
Proliferation by Arresting Cells at the GiM Phase of 
the Cell Cycle 
The effect of a reduced expression ofLIMKl with regard to 
cell proliferation and cell cycle progression was studied. 
LIMKl is expressed in a growth phase-dependent manner, 
which suggests, for example, its possible involvement in the 
regulation of cell growth. 
The growth pattern of induced and non-induced PC3ASL 
and PC3LacZ cells by [3H]thymidine incorporation assay 
was monitored. Results indicated that the inhibition of 
expression of LIMKl led to a block in [3H]thymidine incor-
poration only in PC3ASL cells after about 48 hours of con-
tinuous induction (FIG. 4a), signifying a growth arrest in 
PC3ASL cells. A possible role, for example, of active LIMKl 
sis indicated a higher expression of LIMKl in some cancer-
ous glands in prostatic epithelium (FIGS. le, f, and g). The 
expression ofLIMKl in prostate tissues was localized to the 
basal cells in benign glands (arrows in FIGS. lb, c and d) 50 
compared with a widespread expression and staining in both 
the cytoplasm and the nucleus in the epithelial cells of can-
cerous glands (arrows in FIGS. le, f, and g). These results 
indicate a correlation between over expression ofLIMKl and 
phenotypic differences in prostate tissues. 
The expressed LIMKl in prostate cancer cells was cata-
lytically competent because immunoprecipitated LIMKl 
(FIG. 2, a and b) from PC3 cells was capable of phosphory-
latingrecombinant cofilin (FIG. 2c ), the only known substrate 
ofLIMKl. To determine whether the increased expression of 60 
LIMKl was associated with an increased phosphorylation of 
endogenous cofilin, the phosphorylation status of the native 
cofilin in BPH-1 and PC3 cells was studied using in vivo 
phosphorylation and immunoblotting techniques. Although 
55 in regulating mitosis has been suggested also, based on the 
studies that have shown that the LIMKl activity fluctuates 
with cell cycle progression and attains a maximum level 
during mitosis when LIMKl becomes hyperphosphorylated, 
no significant difference in the expression of cofilin was noted 65 
in these two cell lines an increase of from about 60% to about 
80% in the phosphorylated cofilin was noted in the PC3 cells 
presumably by mitotic Cdks. Induced PC3ASL and PC3LacZ 
cells synchronized at the G /S phase boundary by double 
thymidine block were used and the cell cycle progression was 
monitored by harvesting cells at different time points after the 
release of the block. At about 0 hours, from about 7 5 to about 
78% of the PC3ASL and PC3LacZ cells had progressed to the 
G/S phase of the cell cycle. The remaining from about 22% 
to about 25% of cells had progressed to the G2/M phase of the 
cell cycle, as determined by the higher DNA content in a 
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subpopulation of PC3 cells with inherent chromosomal gain. 
Afterthe release ofthymidine block, both cell types exhibited 
progression through the S phase, about 60% of the cells and 
for the G2/M phase, about 30% of the cells during the next 6 
hours. PC3LacZ cells cycled through the G1 phase as a 5 
gradual increase in the percent of cells in the G 1 phase was 
noted with a concurrent decrease in the total percent of cells 
in the Sand G2/M phases from about the 6'h to about the 14th 
hours (FIG. 4, band c ). In contrast, the PC3ASL cells started 
to accumulate in the GiM phase during this time with about 10 
50% of the cells at 14 hours, indicating a G2/M phase arrest in 
these cells (FIG. 4, band d). The absence of any blockage in 
the cell cycle progression of the PC3LacZ cells (FIG. 4, band 
c) confirms that a threshold concentration of LIMKl is nec-
essary for the passage of cells through the GiM phase of the 15 
cell cycle. These results are also consistent with the [3 H] 
thymidine incorporation data, indicating a growth arrest in 
the PC3ASL cells. 
18 
in PC3 cells was monitored. The induced PC3LacZ cells 
exhibited cell morphology typically observed in PC3 cells, 
with smooth edges and the occasional presence of the filopo-
dial spike-like structures extended from one or both ends of 
the cell and, in some cases, a phase dense border, character-
istic of ruffling lamellipodia around an extensive area of the 
cell periphery (FIG. 6a, arrows). From about 70 to about 90% 
of the induced PC3ASL cells, however, showed a more flat-
tened and irregular shape, with several dark patches at the 
periphery of the cells (arrows in FIG. 6b) that appear to be 
possible adhesion points. Fluorescent staining of actin 
cytoskeleton indicated a prominent actin meshwork, charac-
teristic of lamellipodia formation at the leading edge of the 
induced PC3LacZ cells (FIG. 6c, middle and right); this 
meshwork was also typical of parental PC3 cells (data not 
shown) and of motile cells. Immunolocalization of LIMKl 
(FIG. 6c) showed a perinuclear distribution, with distinct 
targeting to the ruffles at the leading edge of these cells 
Example 10 
Reduced Expression of LIMKl Abolished the 
Invasive Behavior of Prostate Cancer Cells 
20 (arrows in FIG. 6c, left). In contrast, from about 70 to about 
90% of induced PC3ASL cells showed a predominant forma-
tion of discrete stress fibers and focal adhesions typically 
observed in non-motile adherent cells (FIG. 6d, middle and 
The inhibition ofLIMKl expression on the invasive prop- 25 
erty of PC3 cells was studied using an in vitro invasion assay. 
The untransfected PC3 cells indicated that a from about 200% 
right). Distribution of LIMKl in these cells was also peri-
nuclear, with one or more broad areas of accumulation (ar-
rows) at the periphery of the cell (FIG. 6d, left). 
Changes in the adhesion system of the PC3ASL and 
PC3LacZ cells were investigated by monitoring immunolo-
calization of paxillin, an adapter protein associated with focal 
to about a 300% increase of the untransfected PC3 cells were 
invasive and migrated through the Matrigel compared with 
the non-invasive BPH-1 cells (FIG. 5, a and b). A partial 
inhibition ofLIMKl expression in PC3ASL cells resulted in 
a from about 350 to about 550% decrease in the percent of 
invaded cells compared with wild type PC3 and PC3LacZ 
cells (transfection control). This was comparable to the per-
cent ofBPH-1 cells invaded through the membranes. Results, 
as shown in FIG. 3, confirm that LIMKl is necessary to carry 
out the invasive function of PC3 cells. 
Example 11 
The effect of the ectopic expression ofLIMKl and Lacz, 
as the control in non-invasive BPH-1 cells was studied in an 
effort to confirm the role ofLIMKl in promoting invasiveness 
30 adhesions of adherent cells (FIG. 6e). PC3LacZ cells showed 
the presence of paxillin as broad areas surrounding the 
nucleus and small adhesion sites at the cell periphery, which 
overlapped the actin meshwork that forms the lamellipodia 
35 
(arrows in FIG. 6e, left, middle, and right). In contrast, pax-
illin was more centrally localized in PC3ASL cells, with 
frequent accumulation in broad areas between the actin mesh-
work (arrows) representative of stress fibers (FIG. 6, left, 
middle, and right) and the cell boundary. 
40 Published reports indicate an elevated expression of the 
membrane-type matrix metalloproteinase MTl-MMP in 
invasive prostate cancer cells such as PC3 and DU145. 
Because the localization of MTl-MMP to lamellipodia has 
been correlated with the invasive properties of cells, the dis-
45 tribution of this protein in PC3ASL and PC3LacZ cells was 
monitored. Distribution ofMTl-MMP in induced PC3LacZ 
of prostate epithelial cells. Expression of LIMKl in trans-
fected BPH-1 cells after induction by ponasterone A showed 
predominantly cytoplasmic localization of LIMKl (FIG. 5) 
and altered the growth pattern from a clustered and patchy 
appearance (BPHLacZ)) to a more uniform distribution of 
single cells (BPHL) (FIG. 6, i andj). Expression ofLIMKl in 
ponasterone A-treated BPHL cells increased by 1300% the 50 
percentage ofinvasive cells when compared with BPH-1 cells 
expressing Lacz (FIG. 5, a and c). This suggests the acquisi-
tion of a new invasive phenotype by the non-invasive prostate 
cells. Results provided evidence that LIMKl may be one of 
the key proteins that promotes invasiveness and indicates that 55 
the increased expression of LIMKl in PC3 cells may render 
them metastatic. 
was localized to the perinuclear and to the lamellipodia along 
with actin (arrows in FIG. 6g, left, middle, and right) but 
mainly in the perinuclear region in PC3ASL cells FIG. 6h) 
and between actin stress fibers (enlarged box). These results 
indicate that a reduction in LIMKl concentration induced 
beneficial changes in the actin cytoskeleton reorganization, 
the adhesion pattern, and localization of MTl-MMP in PC3 
cells. 
An increase in the expression of LIMKl showed a corre-
lation with the aggressiveness of metastasizing cancer cells. 
For example, expression of LIMKl was higher in metastatic 
PC3 cells and M12 cells when compared with the less-ag-
gressive LNCaP and M21 cells. Consistent with this obser-Example 12 
Altered Expression of LIMKl Changes Cell 
Morphology and Organization of Actin Cytoskeleton 
The dynamic regulation of the actin cytoskeleton and the 
extra-cellular matrix degradation are both required for the 
invasion process of tumor cells to progress. Reductions in 
these processes following the reduced expression of LIMKl 
60 vation, expression ofLIMKl was significantly higher in can-
cerous prostate tissues compared with histologically normal 
pro static epithelium. This may explain the chromosomal gain 
on 7q11.2-q31 that is predominantly found in metastasis of 
prostate tumors. Molecular cytogenetic analysis of pro static 
65 adenocarcinomas indicated an increase in the number of 
patients showing a gain of chromosome 7pq with increasing 
tumor volume. These chromosomal alterations are also found 
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in primary tumors that showed progression after radical pros-
tatectomy, suggesting a possible correlation of LIMKl 
expression as a biomarker for 
While the invention has been described, disclosed, illus-
trated and shown in cancer terms of certain embodiments or 
modifications which it has presumed in practice, the scope of 
the invention is not intended to be, nor should it be deemed to 
be, limited thereby and such other modifications or embodi-
ments as may be suggested by the teachings herein are par-
ticularly reserved especially as they fall within the breadth 
and scope of the claims here appended. 
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CACGGCCCACCGGGCTGTGGCACCGAGCACTCACACACCGTCCGCGTC 45 CAGAGCCGGCCCAGCTGCACACACACACCAT 
CAGGGAGTGGATCCGGGCTGCATGAGCCCAGA GCTCTCGCCCTGCTGTAACCTCTGTCTTGGCAGGGCTGTCCCCTCTTGC 
TGTGAAGAATTCCATCCACGTCGGAGACCGGATCTTGGAAATCAATGG TTCTCCTTGCATGAGCTGGAGGGCCTGTGTG 
CACGCCCATCCGAAATGTGCCCCTGGACGAGA 50 AGTTACGCCCCTTTCCACACGCCGCTGCCCCAGCAACCCTGTTCACGC 
TTGACCTGCTGATTCAGGAAACCAGCCGCCTGCTCCAGCTGACCCTCG TCCACCTGTCTGGTCCATAGCTCCCTGGAGGC 
AGCATGACCCTCACGATACACTGGGCCACGGG TGGGCCAGGAGGCAGCCTCCGAACCATGCCCCATATAACGCTTGGGTG 
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-continued -continued 








GTATTATTTTTTCATACGGCTGCAGCAGCAGCTGCCAGGGGCTTGGGA CA CCC 
SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS, 3 
<210> SEQ ID NO 1 
<211> LENGTH, 3332 
<212> TYPE, DNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 1 
gcgccgagcc ggtttccccg ccggtgtccg agaggcgccc ccggcccggc ccggcccggc 60 
ccgcgccctc cgcccccgcc tccccgggcc ggcggcggtg ggcgagctcg cgggcccggc 120 
cgcccccagc cccagccccg ccgggccccg ccccccgtcg agtgcatgag gttgacgcta 180 
ctttgttgca cctggaggga agaacgtatg ggagaggaag gaagcgagtt gcccgtgtgt 240 
gcaagctgcg gccagaggat ctatgatggc cagtacctcc aggccctgaa cgcggactgg 300 
cacgcagact gcttcaggtg ttgtgactgc agtgcctccc tgtcgcacca gtactatgag 360 
aaggatgggc agctcttctg caagaaggac tactgggccc gctatggcga gtcctgccat 420 
gggtgctctg agcaaatcac caagggactg gttatggtgg ctggggagct gaagtaccac 480 
cccgagtgtt tcatctgcct cacgtgtggg acctttatcg gtgacgggga cacctacacg 540 
ctggtggagc actccaagct gtactgcggg cactgctact accagactgt ggtgaccccc 600 
gtcatcgagc agatcctgcc tgactcccct ggctcccacc tgccccacac cgtcaccctg 660 
gtgtccatcc cagcctcatc tcatggcaag cgtggacttt cagtctccat tgaccccccg 720 
cacggcccac cgggctgtgg caccgagcac tcacacaccg tccgcgtcca gggagtggat 780 
ccgggctgca tgagcccaga tgtgaagaat tccatccacg tcggagaccg gatcttggaa 840 
atcaatggca cgcccatccg aaatgtgccc ctggacgaga ttgacctgct gattcaggaa 900 
accagccgcc tgctccagct gaccctcgag catgaccctc acgatacact gggccacggg 960 
ctggggcctg agaccagccc cctgagctct ccggcttata ctcccagcgg ggaggcgggc 1020 
agctctgccc ggcagaaacc tgtcttgagg agctgcagca tcgacaggtc tccgggcgct 1080 
ggctcactgg gctccccggc ctcccagcgc aaggacctgg gtcgctctga gtccctccgc 1140 
gtagtctgcc ggccacaccg catcttccgg ccgtcggacc tcatccacgg ggaggtgctg 1200 
ggcaagggct gcttcggcca ggctatcaag gtgacacacc gtgagacagg tgaggtgatg 1260 
gtgatgaagg agctgatccg gttcgacgag gagacccaga ggacgttcct caaggaggtg 1320 
aaggtcatgc gatgcctgga acaccccaac gtgctcaagt tcatcggggt gctctacaag 1380 
gacaagaggc tcaacttcat cactgagtac atcaagggcg gcacgctccg gggcatcatc 1440 
US 8,802,649 B2 
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aagagcatgg acagccagta cccatggagc cagagagtga gctttgccaa ggacatcgca 
tcagggatgg cctacctcca ctccatgaac atcatccacc gagacctcaa ctcccacaac 
tgcctggtcc gcgagaacaa gaatgtggtg gtggctgact tcgggctggc gcgtctcatg 
gtggacgaga agactcagcc tgagggcctg cggagcctca agaagccaga ccgcaagaag 
cgctacaccg tggtgggcaa cccctactgg atggcacctg agatgatcaa cggccgcagc 
tatgatgaga aggtggatgt gttctccttt gggatcgtcc tgtgcgagat catcgggcgg 
gtgaacgcag accctgacta cctgccccgc accatggact ttggcctcaa cgtgcgagga 
ttcctggacc gctactgccc cccaaactgc cccccgagct tcttccccat caccgtgcgc 
tgttgcgatc tggaccccga gaagaggcca tcctttgtga agctggaaca ctggctggag 
accctccgca tgcacctggc cggccacctg ccactgggcc cacagctgga gcagctggac 
agaggtttct gggagaccta ccggcgcggc gagagcggac tgcctgccca ccctgaggtc 
cccgactgag ccagggccac tcagctgccc ctgtccccac ctctggagaa tccaccccca 
ccagattcct ccgcgggagg tggccctcag ctgggacagt ggggacccag gcttctcctc 
agagccaggc cctgacttgc cttctcccac cccgtggacc gcttcccctg ccttctctct 
gccgtggccc agagccggcc cagctgcaca cacacaccat gctctcgccc tgctgtaacc 
tctgtcttgg cagggctgtc ccctcttgct tctccttgca tgagctggag ggcctgtgtg 
agttacgccc ctttccacac gccgctgccc cagcaaccct gttcacgctc cacctgtctg 
gtccatagct ccctggaggc tgggccagga ggcagcctcc gaaccatgcc ccatataacg 
cttgggtgcg tgggagggcg cacatcaggg cagaggccaa gttccaggtg tctgtgttcc 
caggaaccaa atggggagtc tggggcccgt tttcccccca gggggtgtct aggtagcaac 
aggtatcgag gactctccaa acccccaaag cagagagagg gctgatccca tggggcggag 
gtccccagtg gctgagcaaa cagccccttc tctcgctttg ggtctttttt ttgtttcttt 
cttaaagcca ctttagtgag aagcaggtac caagcctcag ggtgaagggg gtcccttgag 
ggagcgtgga gctgcggtgc cctggccggc gatggggagg agccggctcc ggcagtgaga 
ggataggcac agtggaccgg gcaggtgtcc accagcagct cagcccctgc agtcatctca 
gagccccttc ccgggcctct cccccaaggc tccctgcccc tcctcatgcc cctctgtcct 
ctgcgttttt tctgtgtaat ctatttttta agaagagttt gtattatttt ttcatacggc 
tgcagcagca gctgccaggg gcttgggatt ttatttttgt ggcgggcggg ggtgggaggg 
ccattttgtc actttgcctc agttgagcat ctaggaagta ttaaaactgt gaagctttct 
cagtgcactt tgaacctgga aaacaatccc aacaggcccg tgggaccatg acttagggag 
gtgggaccca cccaccccca tccaggaacc gtgacgtcca aggaaccaaa cccagacgca 
gaacaataaa ataaattccg tactccccac cc 
<210> SEQ ID NO 2 
<211> LENGTH, 31 
<212> TYPE, DNA 


































<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 2 
gacgacgaca agatggcctc cggtgtggct g 31 
<210> SEQ ID NO 3 
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-continued 
<211> LENGTH, 31 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
primer 
<400> SEQUENCE, 3 
gaggagaagc ccggttcaca aaggcttgcc c 
What is claimed is: 
31 
4. The method of claim 1, wherein said cancer cell metasta-
sis comprises breast cancer cells. 1. A method of treating a subject exhibiting a cancer cell 
metastasis comprising administering to said subject a thera-
peutically effective dose of a composition comprising an 
RNA interfering molecule or a ribozyme that targets SEQ ID 
N0.1. 
15 5. Themethodofclaiml, whereinsaidcancercellmetasta-
2. The method of claim 1, wherein said cancer cell metasta- 20 
sis comprises prostate cancer cells. 
3. The method of claim 1, wherein said cancer cell metasta-
sis comprises ovarian cancer cells. 
sis comprises lung cancer cells. 
6. The method of claim 1, wherein said administering is 
transdermal, intravenous, intraperitoneal or implanted 
administration. 
7. The method of claim 1 wherein said subject is experi-
encing a recurrence of prostate cancer, and said administering 
comprises reducing the proliferation of prostate cancer cells. 
* * * * * 
